The Neurofibromatoses Type I (Von Recklinghausen’s Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neurofibromatoses Type I (Von Recklinghausen’s Disease). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued products.

GlobalData tracks 26 drugs in development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) by 23 companies/universities/institutes. The top development phase for Neurofibromatoses Type I (Von Recklinghausen’s Disease) is phase ii with nine drugs in that stage. The Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline has 24 drugs in development by companies and two by universities/ institutes. Some of the companies in the Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline products market are: Healx, Bristol-Myers Squibb and Therillume.

The key targets in the Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline products market include Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2), Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2), and Hepatocyte Growth Factor Receptor (Proto Oncogene c Met or Tyrosine Protein Kinase Met or HGF/SF Receptor or Scatter Factor Receptor or MET or EC 2.7.10.1).

The key mechanisms of action in the Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline product include Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Inhibitor with seven drugs in Phase III. The Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline products include 12 routes of administration with the top ROA being Oral and six key molecule types in the Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline products market including Small Molecule, and Gene Therapy.

Neurofibromatoses Type I (Von Recklinghausen’s Disease) overview

Neurofibromatosis type 1 (NF1), also called von Recklinghausen’s disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules, and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy, and radiation therapy.

For a complete picture of Neurofibromatoses Type I (Von Recklinghausen’s Disease)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.